Medical Oncology最新文献_第8页

Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology. 免疫毒素工程的进展：现代肿瘤学的精准治疗策略。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-04 DOI: 10.1007/s12032-024-02478-3

Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Hosseininejad-Chafi, Zohre Eftekhari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht

{"title":"Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology.","authors":"Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Hosseininejad-Chafi, Zohre Eftekhari, Mahdi Behdani, Fatemeh Kazemi-Lomedasht","doi":"10.1007/s12032-024-02478-3","DOIUrl":"10.1007/s12032-024-02478-3","url":null,"abstract":"Immunotoxins (ITs) are specialized therapeutic agents designed for targeted treatment, particularly in cancer therapy. They consist of a monoclonal antibody or antibody fragment linked to a potent cytotoxic agent, such as bacterial- or plant-derived toxins like diphtheria toxin, ricin, or pseudomonas exotoxin. The monoclonal antibody component specifically binds to antigens expressed on the surface of target cells, facilitating the internalization of the IT. Once inside the cell, the cytotoxic agent is released, disrupting essential cellular processes and leading to cell death. This targeted approach minimizes damage to healthy tissues while effectively eliminating diseased cells. The production of ITs involves two primary methods: recombinant fusion and chemical conjugation. In recombinant fusion, genetic engineering is used to create a fusion protein that combines the antibody and toxin, ensuring precise control over their ratio and functionality. In chemical conjugation, pre-existing antibodies are chemically linked to toxins, allowing for greater flexibility in combining different antibodies and cytotoxic agents. Each method has its advantages and challenges, influencing the specificity, production complexity, and therapeutic potential of the resulting ITs. As research advances, ITs continue to show promise not only in oncology but also in treating other diseases, including inflammatory conditions and atherosclerosis. The precise targeting and potent effects of ITs make them a valuable tool in the development of new therapeutic strategies.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How mitochondrial dynamics imbalance affects the progression of breast cancer:a mini review. 线粒体动力学失衡如何影响乳腺癌的进展：微型综述。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-09-01 DOI: 10.1007/s12032-024-02479-2

Jingwen Kuang, Hao Liu, Linlin Feng, Yuan Xue, Huiyi Tang, Pengcheng Xu

引用次数: 0

Letter to the editor: comment on "Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment". 致编辑的信：关于 "益生菌衍生银纳米粒子靶向 mTOR/MMP-9/BCL-2/dependent AMPK 激活用于肝癌治疗 "的评论。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-30 DOI: 10.1007/s12032-024-02487-2

Murali Santhoshkumar

引用次数: 0

The treatment landscape of triple-negative breast cancer. 三阴性乳腺癌的治疗前景。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-29 DOI: 10.1007/s12032-024-02456-9

Yi Hu, Chen Wang, Huishi Liang, Jie Li, Qiong Yang

引用次数: 0

Letter to the editor: comment on "Chitosan-loaded piperlongumine nanoparticles and kaempferol enhance the anti-cancer action of doxorubicin in targeting of Ehrlich solid adenocarcinoma: in vivo and in silico modeling study". 致编辑的信：关于 "壳聚糖负载哌隆明纳米粒子和山柰酚增强多柔比星针对艾氏实体腺癌的抗癌作用：体内和硅学模型研究 "的评论。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-29 DOI: 10.1007/s12032-024-02488-1

Adane Desta Gonemo, Ajay Prakash Pasupulla, Murali Santhoshkumar

引用次数: 0

Letter to the editor: Comment on "Anti-cancer potential of casein and its derivatives: novel strategies for cancer treatment". 致编辑的信：关于 "酪蛋白及其衍生物的抗癌潜力：癌症治疗的新策略 "的评论。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-23 DOI: 10.1007/s12032-024-02482-7

Ramya Rajendiran, Murali Santhoshkumar

引用次数: 0

The potential of lenvatinib in breast cancer therapy. 来伐替尼在乳腺癌治疗中的潜力。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-22 DOI: 10.1007/s12032-024-02477-4

Yuefeng Shang, Tong Liu, Wenjing Wang

{"title":"The potential of lenvatinib in breast cancer therapy.","authors":"Yuefeng Shang, Tong Liu, Wenjing Wang","doi":"10.1007/s12032-024-02477-4","DOIUrl":"10.1007/s12032-024-02477-4","url":null,"abstract":"Breast cancer, as a highly prevalent cancer among women, is one of the main causes of female mortality due to cancer. There is a need for more treatment options to improve the survival time of breast cancer patients. Metastasis to distant organs is a standard indicator of advanced breast cancer and a primary cause of breast cancer mortality, making the control of breast cancer metastasis crucial. Targeted therapy, with its advantages of precision, high effectiveness, and minimal side effects, has garnered significant attention as a hot research topic in breast cancer treatment. Among these therapies, anti-angiogenic therapy aim to inhibit tumor angiogenesis, control tumor growth, and reduce metastasis. Additionally, anti-angiogenic therapy can restructure the tumor vasculature, enhancing the effectiveness of other anti-cancer drugs. Lenvatinib, an orally available small molecule multi-targeted tyrosine kinase inhibitor, exerts its anti-tumor effects mainly by inhibiting tumor angiogenesis and tumor cell proliferation. It has been approved for the treatment of thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Due to its multi-targeted nature, lenvatinib not only has direct anti-tumor effects but also possesses immunomodulatory activity, which can enhance the tumor immune response. This makes it a promising candidate for a broad range of cancers. Recent studies have explored the role of lenvatinib in breast cancer, including its various mechanisms of action and its use as a monotherapy or in combination to control breast cancer progression. This review will summarize the molecular mechanisms and research progress of lenvatinib in breast cancer treatment, discussing its potential applications and therapeutic prospects in managing breast cancer.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α. 2-甲氧基雌二醇通过下调 HIF-1α 使抗他莫昔芬的 MCF-7 乳腺癌细胞变得敏感。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-21 DOI: 10.1007/s12032-024-02471-w

Yasmin M Attia, Hamada Ahmed Mokhlis, Ahmed Ismail, Ahmed S Doghish, Mohamed H Sobhy, Sherif S Hassanein, Walaa A El-Dakroury, Amr D Mariee, Salama A Salama, Marwa Sharaky

{"title":"2-methoxyestradiol sensitizes tamoxifen-resistant MCF-7 breast cancer cells via downregulating HIF-1α.","authors":"Yasmin M Attia, Hamada Ahmed Mokhlis, Ahmed Ismail, Ahmed S Doghish, Mohamed H Sobhy, Sherif S Hassanein, Walaa A El-Dakroury, Amr D Mariee, Salama A Salama, Marwa Sharaky","doi":"10.1007/s12032-024-02471-w","DOIUrl":"10.1007/s12032-024-02471-w","url":null,"abstract":"The clinical studies for breast cancer (BC) are now assessing the efficacy of 2-Methoxyestradiol (2-ME), a naturally occurring derivative of estradiol. Our study aimed to explore the potential of combining the 2-ME and tamoxifen (TAM) on sensitization of TAM-resistant cells using LCC2 the TAM-resistant cells as a model and comparing the results to the sensitive cells MCF-7. Sulphorhodamine-B (SRB) assay is used to examine the 2-ME chemo-sensitizing impact on the cytotoxicity of TAM on LCC2 cells. Colorimetric assay kits were used to assess the level of the apoptosis-related markers caspases 3, Bcl2, and Bax in cell lysate. Hypoxia-inducible factor 1 alpha (HIF-1α) expression was measured using western blotting. Total cholesterol and triglyceride (TG) levels were examined colorimetrically, using the BIOLABO kit. The use of 2-ME enhanced the cytotoxic effects of TAM and effectively reversed TAM resistance. This was achieved by inhibiting the expression of HIF-1α, while concurrently increasing the levels of apoptotic marker caspase-3, as well as the pro-apoptotic protein Bax. Additionally, there was a reduction in the levels of Bcl2, an anti-apoptotic protein. Furthermore, a reduction in TG and cholesterol levels was noted. Our findings show that HIF-1α plays an important role in TAM resistance and that suppression of HIF-1α by 2-ME-mediated sensitization of BC-resistant cells to TAM. Therefore, the concurrent administration of TAM/2-ME might potentially serve as a viable therapeutic approach to address TAM resistance and enhance the overall therapy efficacy for patients with BC.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer. 结直肠癌肠道微生物相关干预策略的免疫调节方面。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-20 DOI: 10.1007/s12032-024-02480-9

Makan Cheraghpour, Nayeralsadat Fatemi, Mahdi Shadnoush, Ghazaleh Talebi, Sascha Tierling, Luis G Bermúdez-Humarán

{"title":"Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer.","authors":"Makan Cheraghpour, Nayeralsadat Fatemi, Mahdi Shadnoush, Ghazaleh Talebi, Sascha Tierling, Luis G Bermúdez-Humarán","doi":"10.1007/s12032-024-02480-9","DOIUrl":"10.1007/s12032-024-02480-9","url":null,"abstract":"Colorectal cancer (CRC), the third most common cancer worldwide, develops mainly due to the accumulation of genetic and epigenetic changes over many years. Substantial evidence suggests that gut microbiota plays a significant role in the initiation, progression, and control of CRC, depending on the balance between beneficial and pathogenic microorganisms. Nonetheless, gut microbiota composition by regulating the host immune response may either promote or inhibit CRC. Thus, modification of gut microbiota potentially impacts clinical outcomes of immunotherapy. Previous studies have indicated that therapeutic strategies such as probiotics, prebiotics, and postbiotics enhance the intestinal immune system and improve the efficacy of immunotherapeutic agents, potentially serving as a complementary strategy in cancer immunotherapy. This review discusses the role of the gut microbiota in the onset and development of CRC in relation to the immune response. Additionally, we focus on the effect of strategies manipulating gut microbiome on the immune response and efficacy of immunotherapy against CRC. We demonstrate that manipulation of gut microbiome can enhance immune response and outcomes of immunotherapy through downregulating Treg cells and other immunosuppressive cells while improving the function of T cells within the tumor; however, further research, especially clinical trials, are needed to evaluate its efficacy in cancer treatment.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2023 ACS - LANA lymphedema summit forward momentum; future steps in lymphedema management. 2023 ACS - LANA 淋巴水肿峰会前进的动力；淋巴水肿管理的未来步骤。

IF 2.8 4区医学

Medical Oncology Pub Date : 2024-08-19 DOI: 10.1007/s12032-024-02476-5

Elizabeth Campione, David Doubblestein

引用次数: 0